Cogent Biosciences, Inc. submitted a New Drug Application (NDA) for NonAdvSM in December 2025, with NDA submissions for AdvSM and GIST on track for 2026. Clinical data presentations for PEAK, SUMMIT, and APEX trials expected in 1H 2026. IND applications for pan-KRAS(ON) and selective JAK2 V617F inhibitors expected in 2026. The company has a strong financial position with ~$900 million cash to fund operations until 2028. Cogent will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. Abb Hayden joins Cogent as Senior Vice President, Sales. Bezuclastinib Expanded Access Programs are available for GIST and SM patients. Visit www.cogentbio.com for more information.

Read more at GlobeNewswire: Cogent Biosciences Announces Anticipated 2026 Commercial